Allergen-specific immunotherapy with recombinant grass pollen allergens  Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

Slides:



Advertisements
Similar presentations
Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication 
Advertisements

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy  Monica B. Arvidsson, MD, Olle.
Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies  Marija Geroldinger-Simic, MD, Thomas Zelniker,
Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis  Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,
Allergen immunotherapy: A practice parameter third update
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
High-titer IgE antibody specific for pollen allergens in northern California is associated with both wheezing and total serum IgE  Elizabeth A. Erwin,
Kyoung-Bok Min, MD, PhD, Jin-Young Min, PhD 
Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis  Alain Didier, MD,
Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults  Peter S. Creticos, MD, Jennifer Maloney,
Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy  Gabriela Senti, MD, Nicole Graf, PhD, Susanne Haug, MD, Nadine.
Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.
Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: A meta-analysis–based comparison  Danilo Di.
Is 9 more than 2 also in allergic airway inflammation?
Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,
Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I
SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial  Stephen.
Children with allergic and nonallergic rhinitis have a similar risk of asthma  Bo Lund Krogsgaard Chawes, MD, Klaus Bønnelykke, MD, PhD, Eskil Kreiner-Møller,
Characterization of pollen antigen–induced IL-31 production by PBMCs in patients with allergic rhinitis  Mitsuhiro Okano, MD, Tazuko Fujiwara, BS, Takaya.
Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy  Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy.
Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber  Friedrich Horak, MD, Petra.
Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract  Sheila M. Amar, MD, Ronald.
Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J
Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season  Alexander Kettner, PhD, Gilles DellaCorte, MD,
A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy  Justin M. Skripak, MD, Scott D. Nash, MD, Hannah.
Nonadherence to Asthma Treatment: Getting Unstuck
Reply Journal of Allergy and Clinical Immunology
Debra J. Palmer, PhD, Thomas R. Sullivan, BMa&CompSc(Hons), Michael S
Phillip Lieberman, MD, Michael Tankersley, MD 
Time for a paradigm shift in asthma treatment: From relieving bronchospasm to controlling systemic inflammation  Leif Bjermer, MD  Journal of Allergy.
Modulating allergic response by engineering the major Parietaria allergens  Angela Bonura, PhD, Daniela Di Blasi, PhD, Bianca Barletta, PhD, Cinzia Butteroni,
Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management  Scott H. Sicherer, MD, Hugh A. Sampson, MD  Journal.
Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial  Hendrik.
Sublingual immunotherapy with once-daily grass allergen tablets: A randomized controlled trial in seasonal allergic rhinoconjunctivitis  Stephen R. Durham,
Evaluation of Allergen Immunotherapy
Autophagy: Nobel Prize 2016 and allergy and asthma research
Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis  Thomas B. Casale, MD, William.
Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment
House dust mite sublingual immunotherapy: Results of a US trial
A single intervention for cockroach control reduces cockroach exposure and asthma morbidity in children  Felicia A. Rabito, PhD, MPH, John C. Carlson,
Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy?  Marianne Witten, MD, PhD, Hans-Jørgen Malling, MD, Lars.
Local allergic rhinitis: Allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen  Carmen Rondón, MD, PhD, Natalia.
Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years  Ronald Dahl, MD,
Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies  Marija Geroldinger-Simic, MD, Thomas Zelniker,
Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet  Stephen.
Piotr Kuna, MD, Jadwiga Kaczmarek, MD, Maciej Kupczyk, MD 
Benjamin Chaigne, MD, Hervé Watier, MD, PhD 
Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract  Anil Nanda, MD, Maeve O'Connor, MD,
Reply Journal of Allergy and Clinical Immunology
Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen–induced rhinoconjunctivitis 
Thunderstorm-related asthma attacks
Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis:
An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment  Eli O. Meltzer, MD, Robert B. Berkowitz,
Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy  Johannes Martin Schmid, MD, Peter Adler Würtzen, PhD,
Päivi M. Salo, PhD, Samuel J. Arbes, DDS, MPH, PhD, Patrick W
Macrolide antibiotics and asthma treatment
Asthma: The past, future, environment, and costs
Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy– treated mother  Sabine Flicker, PhD, Katharina Marth, MD, Heinz.
Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding  Sven.
Environmental factors and eosinophilic esophagitis
Sublingual immunotherapy for peanut allergy: Clinical and immunologic evidence of desensitization  Edwin H. Kim, MD, J. Andrew Bird, MD, Michael Kulis,
The GILL study: Glycerin-induced local reactions in immunotherapy
Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule 
Negative affect, medication adherence, and asthma control in children
Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease  Jaclyn Smith, MD, PhD, Emily Owen, MPhil, John Earis, MD,
An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment  Eli O. Meltzer, MD, Robert B. Berkowitz,
Natural history of cow’s milk allergy
Presentation transcript:

Allergen-specific immunotherapy with recombinant grass pollen allergens  Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math, Helmut Fiebig, PhD, Oliver Cromwell, PhD  Journal of Allergy and Clinical Immunology  Volume 116, Issue 3, Pages 608-613 (September 2005) DOI: 10.1016/j.jaci.2005.06.004 Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 1 Symptom scores, medication scores, and symptom-medication scores (SMS) (per protocol set). Evaluation based on a 42-day period encompassing the main pollen exposure, starting 15 days before and ending 26 days after the day with the maximum pollen count. Median values with 25th, 75th (boxes), 10th, and 90th (error bars) percentiles, and outliers (points). A, Active treatment (gray bars); P, placebo treatment (white bars). Mann-Whitney U test. Journal of Allergy and Clinical Immunology 2005 116, 608-613DOI: (10.1016/j.jaci.2005.06.004) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 2 Rhinitis quality of life questionnaire: differences between the means for the 2 treatment groups in the first and second year (full analysis set). The questionnaires completed following the maximum pollen counts in 2002 (gray bars) and 2003 (black bars) were used for analysis. Mann-Whitney U test and P values for 2003 season. Journal of Allergy and Clinical Immunology 2005 116, 608-613DOI: (10.1016/j.jaci.2005.06.004) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions

Fig 3 Grass pollen specific IgE, IgG1, and IgG4 antibody concentrations (full analysis set). Median values with 25th/75th and 10th/90th percentiles represented by boxes and error bars, respectively, and outliers by points. Active (gray bars) and placebo (white bars) groups. Time points: 1, before immunotherapy, 1/2002-2/2002; 2, after initial dosage increase and before pollen season, 4/2002-5/2002; 3, after the pollen season, 7/2002-9/2002; 4, after 12 months, 1/2003-3/2003; 5, before the pollen season, 4/2003-5/2003; 6, at the end of the study, 8/2003-9/2003. ∗∗∗P < .001; NS, nonsignificant. Journal of Allergy and Clinical Immunology 2005 116, 608-613DOI: (10.1016/j.jaci.2005.06.004) Copyright © 2005 American Academy of Allergy, Asthma and Immunology Terms and Conditions